ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 31 filers reported holding ASCENDIS PHARMA A/S in Q4 2016. The put-call ratio across all filers is - and the average weighting 1.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $1,822,000 | +0.7% | 90,000 | 0.0% | 1.96% | +10.1% |
Q3 2016 | $1,809,000 | +51.5% | 90,000 | 0.0% | 1.78% | +43.8% |
Q2 2016 | $1,194,000 | -28.5% | 90,000 | 0.0% | 1.24% | -14.7% |
Q1 2016 | $1,670,000 | +1.3% | 90,000 | 0.0% | 1.45% | +45.4% |
Q4 2015 | $1,649,000 | -88.5% | 90,000 | -88.9% | 1.00% | -72.9% |
Q3 2015 | $14,357,000 | +2.0% | 811,152 | 0.0% | 3.68% | -7.3% |
Q2 2015 | $14,070,000 | +9.0% | 811,152 | 0.0% | 3.97% | +33.5% |
Q1 2015 | $12,911,000 | – | 811,152 | – | 2.97% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |